Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and
tolerance of a new growth hormone (GH) formulation, in the treatment of children born with
retarded intrauterine growth, starting at age 2 to 5 years. Trial Design: The study will be
multicenter, open label, parallel, randomized, Phase IIIb, controlled.